Articles included in the meta-analysis

Report, (country of origin)	Recruitment setting (treatment venue if clinical)	n	Mean age	% men	% white	Type of report	Depression measure(s) (quantification of depression data)
Abbott et al. [24] (US)	Clinical (methadone)	144	35.0	71	15	Cross-s.	BDI, SCID (categorical, continuous)
Araujo et al. [25] (US)	Clinical (detoxification)	68	33.4	73	37	Cross-s.	HRSD (continuous)
Avants et al. [26] (US)	Clinical (methadone)	302	36.7	72	60	Longit.	BDI (continuous)
Avants et al. [27] (US)	Clinical (methadone)	106	34.0	43	60	Cross-s.	BDI (continuous)
Bouhnik et al. [16] (France)	Clinical (buprenorphine)	243	35.0	72	n.r.	Longit.	CES-D (categorical, continuous)
Brienza et al. [1] (US)	Community	528	36.0	76	78	Cross-s.	SCID (categorical)
Campbell et al. [28] (US)	Clinical (behavioral risk reduction)	598	26.0	77	60	Cross-s.	BDI (continuous)
Carrieri et al. [4] (France)	Clinical (buprenorphine)	114	33.6	67	n.r.	Cross-s.	CES-D (continuous)
Darke & Ross [29] (Australia)	Clinical (methadone)	222	29.8	59	n.r.	Cross-s.	CIDI (categorical)
Davis et al. [30] (US)	Clinical (methadone)	97	39.9	100	24	Longit.	BDI (continuous)
Dean et al. [31] (Australia)	Clinical (buprenorphine, methadone	54	29.5	62	n.r.	Longit.	BDI (continuous)
de los Cobos et al. [32] (Spain)	Clinical (detoxification)	40 sample #1	31.4	77	n.r.	Longit.	BDI (continuous)
de los Cobos et al. [32] (Spain)	Clinical (detoxification)	40 sample #2	29.9	85	n.r.	Longit.	BDI (continuous)
Dinwiddie et al. [33] (US)	Community	158	36.5	68	25	Cross-s.	DIS (categorical)
El-Bassel et al. [34] (US)	Clinical (methadone)	201	38.0	50	10	Cross-s	BSI (continuous)
Golub et al. [35] (US)	Community	193	25.8	76	65	Cross-s.	BDI, CES-D (categorical, continuous)
Gossop et al. [36] (UK)	Clinical (mixed)	753	29.0	73	92	Longit.	BSI (continuous)
Grella et al. [37] (US)	Clinical (methadone)	409	39.0	51	24	Cross-s.	CES-D (continuous)
Grella et al. [38] (US)	Clinical (methadone)	427	39.0	51	24	Longit.	CES-D (continuous)
Havard et al. [5] (Australia)	Clinical (mixed)	495	29.2	65	n.r.	Longit.	CIDI (categorical)
Hawkins et al. [20] (US)	Community	514	n.r.	80	21	Cross-s.	GHQ (continuous)
Joe et al. [15] (US)	Clinical (methadone)	981	37.0	61	48	Cross-s.	SCL-90 (continuous)
Johnson et al. [39] (US)	Clinical (mixed)	187	38.7	65	13	Longit.	SCID (categorical)
Johnson et al. [21] (US)	Community	513	38.5	76	55	Cross-s.	BDI (continuous)
Kang & DeLeon [40] (US)	Clinical (methadone)	152	33.0	61	37	Cross-s.	SCL-90 (continuous)
Knowlton et al. [13] (US)	Community	503	39.0	62	4	Cross-s.	CES-D (categorical, continuous)
Knowlton et al. [6] (US)	Community	393	n.r.	64	6	Longit.	CES-D (categorical, continuous)
Kosten et al. [41,42] (US)	Clinical (mixed)	268	27.6	76	48	Longit.	SADS (categorical)
Kosten et al. [43] (US)	Clinical (buprenorphine)	40	30.7	76	93	Longit.	BDI (continuous)
Latkin & Mandell [44] (US)	Community	91	34.0	86	10	Longit.	GHQ (categorical, continuous)
Maddux et al. [14] (US)	Clinical (mixed)	173	49.0	n.r.	<20	Longit.	Zung (continuous)
Mandell et al. [18] (US)	Community	499	36.0	70	2	Cross-s.	GHQ (categorical)
Margolin et al. [45] (US)	Clinical (methadone)	32	34.0	44	53	Longit.	BDI (continuous)
Margolin et al. [46] (US)	Clinical (methadone)	40	42.8	60	35	Longit.	BDI (continuous)
McCusker et al. [47] (US)	Clinical (residential)	162	29.2	71	n.r.	Longit.	DIS, BDI (categorical, continuous)
Metzger et al. [48] (US)	Clinical (methadone)	323	38.0	70	47	Cross-s.	BDI, SCL-90 (continuous)
Mino et al. [49] (Switzerland)	Clinical (methadone)	149	28.1	77	n.r.	Longit.	BDI (categorical)
Musselman & Kell [50] (US)	Clinical (methadone)	71	39.8	61	94	Longit.	MCMI (categorical, continuous)
Nemoto & Foster [51] (US)	Clinical (methadone)	262	33.7	62	13	Cross-s.	PERI (continuous)
Pani et al. [52] (Italy)	Clinical (buprenorphine, methadone)	72	28.0	86	n.r.	Longit.	SCL-90 (continuous)
Perdue et al. [19] (US)	Clinical (mixed)	1228	37.0	66	59	Cross-s.	CES-D (categorical)
Rabkin et al. [9] (US)	Clinical (mixed)	187	38.7	65	13	Longit.	SCID, SCL-90 (categorical, continuous)
Rao et al. [7] (US)	Clinical (methadone) sample 1	727	37.2	60	47	Longit.	SCL-90 (continuous)
Rao et al. [7] (US)	Clinical (methadone) sample 2	432	37.2	59	48	Longit.	SCL-90 (continuous)
Rounsaville et al. [17,53] (US)	Clinical (mixed)	268	27.6	76	48	Longit.	BDI, SADS (categorical, continuous)
Schottenfeld et al. [8] (US)	Clinical (buprenorphine, methadone)	116	32.6	69	78	Longit.	SCID (categorical)
Schottenfeld et al. [54] (US)	Clinical (mixed)	120	32.5	74	64	Cross-s.	BDI (continuous)
Simpson et al. [55] (US)	Community	194	35.0	89	15	Cross-s.	TCU (continuous)
Steer et al. [56] (US)	Community	1290	35.3	76	18	Cross-s	BDI (continuous)
Strain et al. [57] (US)	Clinical (methadone)	66	36.0	55	79	Cross-s.	SADS (categorical)
Strain et al. [58] (US)	Clinical (methadone)	58	34.3	67	41	Longit.	BDI (continuous)
Strathdee et al. [59] (Canada)	Community	281	34.9	68	58	Cross-s.	CES-D (categorical)
Teesson et al. [10] (Australia)	Clinical (mixed)	615	29.3	66	n.r.	Cross-s.	CIDI (categorical)
Torrens et al. [60] (Spain)	Clinical (detoxification)	62	25.9	76	n.r.	Longit.	BDI (continuous)
Wild et al. [3] (Canada)	Community	679	34.7	67	68	Cross-s.	CIDI (categorical)

n.r. = not reported. For the purpose of this meta-analysis, reports described as longitudinal (longit.) contributed data on change in depressive symptoms and/or depression and future drug use/impairment. Abbreviations for the depression measures are explained in the text along with the relevant citation.